461 reports of this reaction
1.8% of all TIOTROPIUM BROMIDE INHALATION SPRAY reports
#11 most reported adverse reaction
FATIGUE is the #11 most commonly reported adverse reaction for TIOTROPIUM BROMIDE INHALATION SPRAY, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.. There are 461 FDA adverse event reports linking TIOTROPIUM BROMIDE INHALATION SPRAY to FATIGUE. This represents approximately 1.8% of all 25,050 adverse event reports for this drug.
Patients taking TIOTROPIUM BROMIDE INHALATION SPRAY who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for TIOTROPIUM BROMIDE INHALATION SPRAY, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for TIOTROPIUM BROMIDE INHALATION SPRAY:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 461 FDA reports for TIOTROPIUM BROMIDE INHALATION SPRAY. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 1.8% of all adverse event reports for TIOTROPIUM BROMIDE INHALATION SPRAY, making it a notable side effect.
If you experience fatigue while taking TIOTROPIUM BROMIDE INHALATION SPRAY, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.